Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organogenesis Apligraf U.S. Shipments By Novartis To Begin In June

This article was originally published in The Gray Sheet

Executive Summary

Organogenesis Apligraf skin graft shipments are scheduled to begin in June following FDA approval May 22 for treatment of venous ulcers.

You may also be interested in...



Organogenesis Buyback Of Apligraf Rights Could Create Acquisition Target

Organogenesis is seeking to raise $20-40 mil. to repurchase worldwide marketing rights to its Apligraf bi-layered skin substitute from Novartis and avoid a bankruptcy filing by year-end

Organogenesis Buyback Of Apligraf Rights Could Create Acquisition Target

Organogenesis is seeking to raise $20-40 mil. to repurchase worldwide marketing rights to its Apligraf bi-layered skin substitute from Novartis and avoid a bankruptcy filing by year-end

Apligraf Reduces Healing Time For Diabetic Foot Ulcers By 30%

Organogenesis' Apligraf living skin construct reduces the time it takes diabetic foot ulcers to heal by almost one-third, the company says.

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel